BioStock

Prenumeration

SynAct Pharma refines development strategy and extends financial runway through 2026

2025-06-05 15:40:00

On June 4, SynAct Pharma hosted a Capital Markets Day to present its refined development strategy, including the launch of development initiatives in polymyalgia rheumatica. On the same day, the company announced a directed share issue of approximately SEK 37 million, along with a SEK 30 million credit facility – together securing a financial runway through the end of 2026.

Read the article at biostock.se

https://biostock.se/2025/06/synact-pharma-refines-development-strategy-and-extends-financial-runway-through-2026/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden